VIVS · VivoSim Labs, INC.
$0.32
-0.01 (-1.71%)
At close · Aug 14
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has performed an analysis and concluded that substantial doubt exists about our ability to continue as a going concern. Separately, our independent registered public accounting firm included in its opinion for the year ended March 31, 2026 an explanatory paragraph referring to our recurring losses from operations and expressing substantial doubt in our ability to continue as a going concern without additional capital becoming available.”View the 10-Q filed Aug 12, 2026
Market Cap
$4.79M
Shares
14.85M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Keith Murphy | Executive Chairman | $1,165,657 |
| Thomas Hess | Former Chief Financial Officer | $114,975 |
| Norman Staskey | Chief Financial Officer | $20,925 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Keith Murphy | Executive Chairman | $681,136 |
| Thomas Jurgensen | Former General Counsel and Corporate Secretary | $509,900 |
| Jeffrey Miner | Former Chief Scientific Officer | $320,031 |
| Thomas Hess | Chief Financial Officer | $199,322 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Keith Murphy | Executive Chairman | $621,448 |
| Thomas Jurgensen | Former General Counsel and Corporate Secretary | $465,974 |
| Jeffrey Miner | Former Chief Scientific Officer | $315,753 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Keith Murphy | Executive Chairman | $1,260,144 |
| Thomas Jurgensen | Former General Counsel and Corporate Secretary | $812,083 |
| Jeffrey Miner | Former Chief Scientific Officer | $747,027 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Keith Murphy | Executive Chairman | $2,360,645 |
| Taylor Crouch | Former Chairman, Chief Executive Officer, President | $1,609,153 |
| Jennifer Kinsbruner Bush | Former SVP, General Counsel, Corporate Secretary and Compliance Officer | $1,021,759 |
| Jeffrey Miner | Chief Scientific Officer^(^^7)^ | $953,317 |
| Thomas Jurgensen | General Counsel and Corporate Secretary^(^^6)^ | $695,683 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Taylor Crouch | Former Chairman, Chief Executive Officer, President | $1,643,409 |
| Steven Hughes | Former Chief Medical Officer | $1,313,492 |
| Craig Kussman | Former Chief Financial Officer | $880,752 |
| Paul Gallant | — | $834,144 |
| Jennifer Kinsbruner Bush | Former SVP, General Counsel, Corporate Secretary and Compliance Officer | $792,083 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Taylor Crouch | Chairman, Chief Executive Officer, President | $2,924,208 |
| Craig Kussman | Chief Financial Officer | $1,553,083 |
| Jennifer Kinsbruner Bush | SVP, General Counsel, Corporate Secretary and Compliance Officer | $1,482,635 |
| Former General Manager | — | $1,169,909 |
| Steven Hughes | Former Chief Medical Officer | $433,135 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Tony Lialin | Chief Commercial Officer | Appointed | 2025-08-14 |
| Vaidehi Joshi | Board of Directors | Resigned | 2025-03-26 |
| Tomas Hess | President, Chief Financial Officer and Principal Financial Officer | Resigned | 2024-12-31 |
| Norman Staskey | principal accounting officer | Appointed | 2024-12-31 |
| Norman Staskey | President, Chief Financial Officer and Principal Financial Officer | Appointed | 2024-12-31 |
| Vaidehi Joshi | Class I director | Appointed | 2024-11-22 |
| Alison Tjosvold Milhous | Class I director | Appointed | 2024-11-22 |
| Adam Stern | Class III director | Appointed | 2023-11-03 |
| Keith Murphy | Class III director | Appointed | 2023-11-03 |
| Tom Jurgensen | General Counsel and Corporate Secretary | Terminated | 2023-09-12 |
| Jeffrey Miner | Chief Scientific Officer | Terminated | 2023-08-22 |
| Tom Jurgensen | General Counsel and Corporate Secretary | Terminated | 2023-08-22 |
| David Gobel | Class II director | Appointed | 2022-10-14 |
| Douglas Jay Cohen | Class II director | Appointed | 2022-10-14 |
Key facts
CIK
1497253
CUSIP
68620A302
13F (30d)
24 filings
24 filers
Visit website
Investor relations